Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia

M. W. DeGregorio; C. J. Carrera; J. C. Klock; C. H. Pegelow; J. R. Wilbur

Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia

M. W. DeGregorio, C. J. Carrera, J. C. Klock, C. H. Pegelow, J. R. Wilbur

Research output: Contribution to journal › Article › peer-review

Abstract

Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m ², and regimen B a loading dose of 15 mg/m ² followed by 35 mg/m ² infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.

Original language	English (US)
Pages (from-to)	2085-2088
Number of pages	4
Journal	Cancer Treatment Reports
Volume	66
Issue number	12
State	Published - 1982
Externally published	Yes

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia'. Together they form a unique fingerprint.

Cite this

@article{d20e9e036ae84a38b3c01ab1c783a0a2,

title = "Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia",

abstract = "Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.",

author = "DeGregorio, {M. W.} and Carrera, {C. J.} and Klock, {J. C.} and Pegelow, {C. H.} and Wilbur, {J. R.}",

year = "1982",

language = "English (US)",

volume = "66",

pages = "2085--2088",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia

AU - DeGregorio, M. W.

AU - Carrera, C. J.

AU - Klock, J. C.

AU - Pegelow, C. H.

AU - Wilbur, J. R.

PY - 1982

Y1 - 1982

N2 - Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.

AB - Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0020366688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020366688&partnerID=8YFLogxK

M3 - Article

C2 - 6958366

AN - SCOPUS:0020366688

VL - 66

SP - 2085

EP - 2088

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -